PMID- 26910242
OWN - NLM
STAT- MEDLINE
DCOM- 20170111
LR  - 20220318
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 103
IP  - 4
DP  - 2016 Apr
TI  - Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic 
      hematopoietic stem cell transplantation for aplastic anemia from human leukocyte 
      antigen-identical sibling.
PG  - 461-8
LID - 10.1007/s12185-016-1960-z [doi]
AB  - The standard conditioning regimen in allogeneic hematopoietic stem cell 
      transplantation (HSCT) for aplastic anemia from a human leukocyte antigen 
      (HLA)-identical sibling has been high-dose cyclophosphamide (CY 200 mg/kg). In 
      the present study, results for 203 patients with aplastic anemia aged 16 years or 
      older who underwent allogeneic HSCT from HLA-identical siblings were 
      retrospectively analyzed using the registry database of Japan Society for 
      Hematopoietic Cell Transplantation. Conditioning regimens were defined as a (1) 
      high-dose CY (200 mg/kg or greater)-based (n = 117); (2) reduced-dose CY (100 
      mg/kg or greater, but less than 200 mg/kg)-based (n = 38); and (3) low-dose CY 
      (less than 100 mg/kg)-based (n = 48) regimen. Patient age and the proportion of 
      patients receiving fludarabine were significantly higher in the reduced- and 
      low-dose CY groups than the high-dose CY group. Engraftment was comparable among 
      the groups. Five-year overall survival (OS) tended to be higher in the low-dose 
      CY group [93.0 % (95 % CI 85.1-100.0 %)] than the high-dose CY [84.2 % (95 % CI 
      77.1-91.3 %)] or reduced-dose CY groups [83.8 % (95 % CI 71.8-95.8 %); P = 
      0.214]. Age-adjusted OS was higher in the low-dose CY group than the high- and 
      reduced-dose CY groups with borderline significance (P = 0.067). These results 
      suggest that CY dose can safely be reduced without increasing graft rejection by 
      adding fludarabine in allogeneic HSCT for aplastic anemia from an HLA-identical 
      sibling.
FAU - Mori, Takehiko
AU  - Mori T
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. tmori@a3.keio.jp.
FAU - Koh, Hideo
AU  - Koh H
AD  - Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
FAU - Onishi, Yasushi
AU  - Onishi Y
AD  - Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, 
      Japan.
FAU - Kako, Shinichi
AU  - Kako S
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama, Japan.
FAU - Onizuka, Makoto
AU  - Onizuka M
AD  - Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, 
      Japan.
FAU - Kanamori, Heiwa
AU  - Kanamori H
AD  - Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
FAU - Ozawa, Yukiyasu
AU  - Ozawa Y
AD  - Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, 
      Aichi, Japan.
FAU - Kato, Chiaki
AU  - Kato C
AD  - Department of Hematology, Meitetsu Hospital, Aichi, Japan.
FAU - Iida, Hiroatsu
AU  - Iida H
AD  - Division of Cell Therapy, National Hospital Organization D, Aichi, Japan.
FAU - Suzuki, Ritsuro
AU  - Suzuki R
AD  - Department of HSCT Data Management, Nagoya University Graduate School of 
      Medicine, Nagoya, Japan.
FAU - Ichinohe, Tatsuo
AU  - Ichinohe T
AD  - Department of Hematology and Oncology, Research Institute for Radiation Biology 
      and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Kanda, Yoshinobu
AU  - Kanda Y
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama, Japan.
FAU - Maeda, Tetsuo
AU  - Maeda T
AD  - Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
FAU - Nakao, Shinji
AU  - Nakao S
AD  - Cellular Transplantation Biology, Kanazawa University Graduate School of Medical 
      Science, Kanazawa, Japan.
FAU - Yamazaki, Hirohito
AU  - Yamazaki H
AD  - Cellular Transplantation Biology, Kanazawa University Graduate School of Medical 
      Science, Kanazawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160224
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Myeloablative Agonists)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anemia, Aplastic/complications/*therapy
MH  - Cyclophosphamide/*therapeutic use
MH  - Female
MH  - Graft vs Host Disease/diagnosis/etiology
MH  - HLA Antigens/analysis
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/administration & dosage/therapeutic use
MH  - Siblings
MH  - Survival Analysis
MH  - Transplantation Conditioning/*methods
MH  - Vidarabine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Aplastic anemia
OT  - Cyclophosphamide
OT  - Fludarabine
EDAT- 2016/02/26 06:00
MHDA- 2017/01/12 06:00
CRDT- 2016/02/25 06:00
PHST- 2015/11/04 00:00 [received]
PHST- 2016/02/10 00:00 [accepted]
PHST- 2016/02/10 00:00 [revised]
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2017/01/12 06:00 [medline]
AID - 10.1007/s12185-016-1960-z [pii]
AID - 10.1007/s12185-016-1960-z [doi]
PST - ppublish
SO  - Int J Hematol. 2016 Apr;103(4):461-8. doi: 10.1007/s12185-016-1960-z. Epub 2016 
      Feb 24.